Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts

The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help shore up sales of their Eylea franchise amid biosimilar encroachment.